<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740362</url>
  </required_header>
  <id_info>
    <org_study_id>A3921006</org_study_id>
    <nct_id>NCT01740362</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function</brief_title>
  <official_title>Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or
      severe renal impairment, who do not require hemodialysis, compared to healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</measure>
    <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
    <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CL R)</measure>
    <time_frame>0 (Pre-dose) to 12 hours post-dose, 12 to 24 hours post-dose</time_frame>
    <description>Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with mild (&gt;50 and ≤80 mL/min) renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with moderate (≥30 and ≤50 mL/min) renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with severe (&lt;30 mL/min) renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg (2 x 5 mg tablets), single dose</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg (2 x 5 mg tablets), single dose</description>
    <arm_group_label>Mild renal impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg (2 x 5 mg tablets), single dose</description>
    <arm_group_label>Moderate renal impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg (2 x 5 mg tablets), single dose</description>
    <arm_group_label>severe renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with normal renal function: Subjects must be healthy with estimated
             creatinine clearance &gt;80 mL/min

          -  Subjects with renal impairment: Subjects should be in good general health commensurate
             with the population with chronic kidney disease

        Exclusion Criteria:

          -  Kidney transplant patients

          -  Subjects with any condition possibly affecting drug absorption

          -  Subjects with malignancies with the exception of adequately treated basal cell
             carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921006&amp;StudyName=Pharmacokinetics%20Of%20CP-690%2C550%20In%20Patients%20With%20Impaired%20Renal%20Function%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <results_first_submitted>December 3, 2012</results_first_submitted>
  <results_first_submitted_qc>December 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2013</results_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 (Normal Renal Function)</title>
          <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 (Mild Renal Insufficiency)</title>
          <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="P3">
          <title>CP-690,550 (Moderate Renal Insufficiency)</title>
          <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="P4">
          <title>CP-690,550 (Severe Renal Insufficiency)</title>
          <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 (Normal Renal Function)</title>
          <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 (Mild Renal Insufficiency)</title>
          <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="B3">
          <title>CP-690,550 (Moderate Renal Insufficiency)</title>
          <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="B4">
          <title>CP-690,550 (Severe Renal Insufficiency)</title>
          <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="9.7"/>
                    <measurement group_id="B2" value="61.2" spread="2.8"/>
                    <measurement group_id="B3" value="53.5" spread="11.1"/>
                    <measurement group_id="B4" value="59.0" spread="14.6"/>
                    <measurement group_id="B5" value="56.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
        <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
        <population>Analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 (Normal Renal Function)</title>
            <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 (Mild Renal Insufficiency)</title>
            <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 (Moderate Renal Insufficiency)</title>
            <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 (Severe Renal Insufficiency)</title>
            <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
          <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>Analysis set included all participants who received study medication.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268" spread="71.5"/>
                    <measurement group_id="O2" value="370" spread="109"/>
                    <measurement group_id="O3" value="396" spread="154"/>
                    <measurement group_id="O4" value="615" spread="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1 way Analysis of Variance (ANOVA) on natural log-transformed AUC(0-∞) analyzed using linear model with degrees of renal impairment(creatinine clearance[CLcr, discrete]) evaluated using blood samples collected at screening as fixed effect. Statistical Analysis System (SAS) mixed procedure (PROC MIXED) was used. Anti-log of adjusted mean difference (CP-690,550[mild renal insufficiency] - CP-690,550[normal renal function]), 90% confidence interval (CI) were taken to estimate mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>137.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.77</ci_lower_limit>
            <ci_upper_limit>194.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA on natural log-transformed AUC (0 - ∞) were analyzed using linear model containing degrees of renal impairment (CLcr, discrete) calculated using blood samples collected at screening as fixed effects. SAS procedure PROC MIXED was used for analysis. Anti-log of the adjusted mean difference (CP-690,550 [moderate renal insufficiency] - CP-690,550 [normal renal function]) and its corresponding 90% CI were taken to estimate the mean ratio and corresponding 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>142.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.53</ci_lower_limit>
            <ci_upper_limit>202.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA on natural log-transformed AUC (0 - ∞) were analyzed using linear model containing degrees of renal impairment (CLcr, discrete) calculated using blood samples collected at screening as fixed effects. SAS procedure PROC MIXED was used for analysis. Anti-log of the adjusted mean difference (CP-690,550 [severe renal insufficiency] - CP-690,550 [normal renal function]) and its corresponding 90% CI were taken to estimate the mean ratio and corresponding 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>222.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>157.02</ci_lower_limit>
            <ci_upper_limit>315.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
        <population>Analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 (Normal Renal Function)</title>
            <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 (Mild Renal Insufficiency)</title>
            <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 (Moderate Renal Insufficiency)</title>
            <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 (Severe Renal Insufficiency)</title>
            <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>Analysis set included all participants who received study medication.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" spread="25.3"/>
                    <measurement group_id="O2" value="87.3" spread="23.2"/>
                    <measurement group_id="O3" value="104" spread="47.5"/>
                    <measurement group_id="O4" value="111" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA on natural log-transformed Cmax were analyzed using linear model containing degrees of renal impairment (CLcr, discrete) calculated using blood samples collected at screening as fixed effects. SAS procedure PROC MIXED was used for analysis. Anti-log of the adjusted mean difference (CP-690,550 [mild renal insufficiency] - CP-690,550 [normal renal function]) and its corresponding 90% CI were taken to estimate the mean ratio and corresponding 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric mean</param_type>
            <param_value>93.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.22</ci_lower_limit>
            <ci_upper_limit>129.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA on natural log-transformed Cmax were analyzed using linear model containing degrees of renal impairment (CLcr, discrete) calculated using blood samples collected at screening as fixed effects. SAS procedure PROC MIXED was used for analysis. Anti-log of the adjusted mean difference (CP-690,550 [moderate renal insufficiency] - CP-690,550 [normal renal function]) and its corresponding 90% CI were taken to estimate the mean ratio and corresponding 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric mean</param_type>
            <param_value>104.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.18</ci_lower_limit>
            <ci_upper_limit>144.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA on natural log-transformed Cmax were analyzed using linear model containing degrees of renal impairment (CLcr, discrete) calculated using blood samples collected at screening as fixed effects. SAS procedure PROC MIXED was used for analysis. Anti-log of the adjusted mean difference (CP-690,550 [severe renal insufficiency] - CP-690,550 [normal renal function]) and its corresponding 90% CI were taken to estimate the mean ratio and corresponding 90% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of adjusted geometric mean</param_type>
            <param_value>117.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.91</ci_lower_limit>
            <ci_upper_limit>163.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
        <population>Analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 (Normal Renal Function)</title>
            <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 (Mild Renal Insufficiency)</title>
            <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 (Moderate Renal Insufficiency)</title>
            <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 (Severe Renal Insufficiency)</title>
            <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>Analysis set included all participants who received study medication.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose</time_frame>
        <population>Analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 (Normal Renal Function)</title>
            <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 (Mild Renal Insufficiency)</title>
            <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 (Moderate Renal Insufficiency)</title>
            <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 (Severe Renal Insufficiency)</title>
            <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>Analysis set included all participants who received study medication.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.363"/>
                    <measurement group_id="O2" value="2.83" spread="0.857"/>
                    <measurement group_id="O3" value="2.88" spread="0.653"/>
                    <measurement group_id="O4" value="3.77" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CL R)</title>
        <description>Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.</description>
        <time_frame>0 (Pre-dose) to 12 hours post-dose, 12 to 24 hours post-dose</time_frame>
        <population>Analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 (Normal Renal Function)</title>
            <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 (Mild Renal Insufficiency)</title>
            <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 (Moderate Renal Insufficiency)</title>
            <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 (Severe Renal Insufficiency)</title>
            <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CL R)</title>
          <description>Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.</description>
          <population>Analysis set included all participants who received study medication.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="16.2"/>
                    <measurement group_id="O2" value="84.7" spread="28.7"/>
                    <measurement group_id="O3" value="27.4" spread="15.9"/>
                    <measurement group_id="O4" value="19.9" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 (Normal Renal Function)</title>
          <description>Participants with normal renal function who had creatinine clearance greater than (&gt;) 80 milliliter/minute (mL/min), received single oral dose of CP-690,550 tablet 10 milligram (mg) orally.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 (Mild Renal Insufficiency)</title>
          <description>Participants with mild renal insufficiency who had creatinine clearance &gt;50 mL/min but less than or equal to (=&lt;) 80 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="E3">
          <title>CP-690,550 (Moderate Renal Insufficiency)</title>
          <description>Participants with moderate renal insufficiency who had creatinine clearance &gt;=30 mL/min but =&lt;50 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
        <group group_id="E4">
          <title>CP-690,550 (Severe Renal Insufficiency)</title>
          <description>Participants with severe renal insufficiency who had creatinine clearance &lt;30 mL/min, received single oral dose of CP-690,550 tablet 10 mg orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

